TransMedics Group, Inc. — Q2 2023 Form 10-Q
Business context and reporting period
Quarter ended June 30, 2023; unaudited results. TransMedics is a commercial-stage medical technology company selling its Organ Care System (OCS) for heart, lung and liver transplants and providing organ retrieval and management services through its National OCS Program (NOP). The company reports as one operating segment.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $52.5 million | $20.5 million | $94.0 million | $36.4 million |
| Gross profit | $36.7 million | $14.4 million | $65.5 million | $26.5 million |
| Gross margin | 70.0% | 69.9% | 69.7% | 72.7% |
| Operating loss | $0.9 million | $9.7 million | $3.0 million | $19.1 million |
| Net loss | $1.0 million | $11.5 million | $3.6 million | $22.1 million |
| Operating cash flow | Not separately presented | Not separately presented | $(14.5) million | $(27.5) million |
- Q2 revenue increased approximately 156% year over year; six-month revenue increased approximately 158%. Product revenue was $42.5 million in Q2 and $76.5 million for six months; service revenue was $10.0 million and $17.6 million, respectively.
- Management attributed growth primarily to higher U.S. OCS Liver and OCS Heart sales and increased NOP utilization. U.S. revenue was $48.9 million in Q2 and $86.4 million for six months; NOP participants generated approximately 95% of U.S. revenue in both 2023 periods.
- Q2 product gross margin was 80% versus 77% a year earlier; service gross margin was 28% versus 20%. For six months, product margin was 79% versus 77%, while service margin was 28% versus 30%.
- Cash was $582.2 million at June 30, 2023, versus $201.2 million at year-end 2022. Cash, cash equivalents and restricted cash increased by $381.3 million during the six months, primarily reflecting note issuance proceeds.
- At June 30, principal debt comprised $460 million of 1.50% convertible notes due 2028 and $60 million under the CIBC credit agreement. Carrying amounts were $445.8 million and $58.9 million, respectively. The notes’ disclosed fair value was $528.3 million.
- Current assets were $662.7 million and current liabilities $32.0 million. Stockholders’ equity was $145.2 million; accumulated deficit was $482.3 million.
Changes versus prior comparable periods
- Revenue growth substantially improved results: Q2 net loss narrowed to $1.0 million from $11.5 million, and six-month net loss narrowed to $3.6 million from $22.1 million.
- Q2 selling, general and administrative expense rose $12.0 million to $29.4 million, driven by expanded headcount, stock-based compensation, NOP logistics and professional fees. Six-month SG&A increased $23.0 million to $54.3 million.
- Six-month research, development and clinical-trial expense was broadly flat at $14.2 million. Operating cash use declined year over year, though receivables and inventory growth used cash.
- In May 2023, the company issued $460 million of convertible notes. Net proceeds after issuance costs and $52.1 million for capped calls were approximately $393.3 million. The initial conversion price is about $94 per share; capped calls have a $141.88 cap price.
Outlook, risks and unusual items
- No quantified revenue or earnings guidance was provided. Management expects continued losses in the foreseeable future and anticipates investment in commercial expansion, NOP, manufacturing and sterilization capacity, product development and regulatory work. It expects cash to fund operations, capital expenditures and debt service for at least 12 months after filing.
- On August 1, 2023, the company agreed to acquire Summit Aviation and Northside Property Group, subject to closing conditions; it also acquired two fixed-wing aircraft in July and August. On August 2, it acquired certain lung and heart perfusion technology assets from Bridge to Life. The company expects to use approximately $70 million of cash for these acquisitions. Summit would add aviation operations to the NOP; integration, operating and aviation risks are highlighted.
- Key risks include continued operating losses, OCS market adoption and reimbursement, scaling manufacturing and sterilization, reliance on limited-source suppliers, transport and logistics execution, regulatory requirements, competition, and economic or supply-chain disruption. The company also notes potential dependence on additional financing despite its current cash position.
- During Q2, the company identified an intrusion into portions of its IT network and unauthorized theft of employee and financial data. It reported no patient-related data stored on its network and said the incident had not materially affected operations; future impacts could be material.
- The CIBC facility is secured by substantially all company and guarantor assets, including intellectual property, and includes liquidity and revenue covenants. The company reported compliance at June 30, 2023. A remaining unconditional purchase commitment was $7.0 million; no material legal proceedings or accrued indemnification liabilities were reported.
Important facts for investors to verify
- Whether revenue growth and NOP utilization continue, particularly given the high share of U.S. revenue tied to NOP participants and organ mix.
- Whether margins hold as service activity, transportation costs and operating scale change; six-month total gross margin declined year over year.
- Cash use, receivables and inventory growth, and the company’s ability to meet its 12-month liquidity assessment and CIBC covenants.
- Final terms, closing and integration costs for the announced acquisitions, including the expected approximately $70 million cash outlay and aviation operating risks.
- Potential dilution or cash obligations under the convertible notes, including conversion, fundamental-change repurchase and debt-service provisions.
- Remediation and any subsequent consequences of the cybersecurity incident, and resilience of critical suppliers, sterilization capacity and transportation operations.